Biogen (BIIB.US) Q3 results exceed expectations, rare disease drug sales remain strong

智通财经APP has learned that Biogen (BIIB.US) released its third-quarter results before market open on October 28: total revenue reached $2.804 billion, representing an 11% year-on-year increase and 10% growth at constant currency, surpassing market expectations of $2.63 billion to $2.68 billion; adjusted diluted earnings per share were $2.62, higher than the expected approximately $1.99, but down 46% year-on-year. Strong demand for the company’s rare disease and Alzheimer’s drugs helped offset the decline in sales of multiple sclerosis treatments.